Patents by Inventor Christine E. Brotherton-Pleiss
Christine E. Brotherton-Pleiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9580411Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: GrantFiled: March 27, 2015Date of Patent: February 28, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Huifen Chen, Shaoqing Chen, Zhi Chen, Shawn David Erickson, Anthony Estrada, Kyungjin Kim, Hongju Li, Allen John Lovey, Joseph P. Lyssikatos, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
-
Patent number: 9556147Abstract: This application discloses compounds according to generic Formula I: (I) wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: GrantFiled: March 3, 2014Date of Patent: January 31, 2017Assignee: HOFFMANN-LA INC.Inventors: Christine E. Brotherton-Pleiss, Rama K. Kondru, Francisco Javier Lopez-Tapia, Yan Lou
-
Patent number: 9499548Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: GrantFiled: September 10, 2013Date of Patent: November 22, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: Christine E. Brotherton-Pleiss, Ramona Hilgenkamp, Rama K. Kondru, Francisco Javier Lopez-Tapia, Yan Lou
-
Patent number: 9388172Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.Type: GrantFiled: May 8, 2015Date of Patent: July 12, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Shawn David Erickson, Hongju Li, Sung-Sau So
-
Patent number: 9359337Abstract: The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R3, X and Y are as defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: GrantFiled: May 14, 2015Date of Patent: June 7, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Yimin Qian
-
Patent number: 9353096Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.Type: GrantFiled: April 10, 2015Date of Patent: May 31, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Kyungjin Kim, Hongju Li, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
-
Publication number: 20160002206Abstract: This application discloses compounds according to generic Formula I: (I) wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: ApplicationFiled: March 3, 2014Publication date: January 7, 2016Inventors: Christine E. Brotherton-Pleiss, Rama K. Kondru, Francisco Javier Lopez-Tapia, Yan Lou
-
Publication number: 20150246906Abstract: The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R3, X and Y are as defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: May 14, 2015Publication date: September 3, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: CHRISTINE E. BROTHERTON-PLEISS, ZHI CHEN, SHAWN DAVID ERICKSON, YIMIN QIAN
-
Publication number: 20150239873Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.Type: ApplicationFiled: May 8, 2015Publication date: August 27, 2015Applicant: Hoffmann-La Roche Inc.Inventors: CHRISTINE E. BROTHERTON-PLEISS, SHAWN DAVID ERICKSON, HONGJU LI, SUNG-SAU SO
-
Publication number: 20150218141Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.Type: ApplicationFiled: April 16, 2015Publication date: August 6, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Kyungjin Kim, Hongju Li, Allen John Lovey, Yimin Qian, Sung-Sau SO, Peter Michael Wovkulich, Lin Yi
-
Publication number: 20150218144Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.Type: ApplicationFiled: April 10, 2015Publication date: August 6, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Kyungjin Kim, Hongju Li, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
-
Publication number: 20150210704Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: ApplicationFiled: September 10, 2013Publication date: July 30, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Ramona Hilgenkamp, Rama K. Kondru, Francisco Javier Lopez-Tapia, Yan Lou
-
Publication number: 20150197509Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: ApplicationFiled: March 27, 2015Publication date: July 16, 2015Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.Inventors: Christine E. BROTHERTON-PLEISS, Huifen CHEN, Shaoqing CHEN, Zhi CHEN, Shawn David ERICKSON, Anthony ESTRADA, Kyungjin KIM, Hongju LI, Allen John LOVEY, Joseph P. LYSSIKATOS, Yimin QIAN, Sung-Sau SO, Peter Michael WOVKULICH, Lin YI, I
-
Patent number: 8940741Abstract: This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: GrantFiled: March 1, 2013Date of Patent: January 27, 2015Assignee: Hoffmann-La Roche Inc.Inventors: Steven Joseph Berthel, Roland Joseph Billedeau, Christine E. Brotherton-Pleiss, Fariborz Firooznia, Stephen Deems Gabriel, Xiaochun Han, Ramona Hilgenkamp, Saul Jaime-Figueroa, Buelent Kocer, Francisco Javier Lopez-Tapia, Yan Lou, Lucja Orzechowski, Timothy D. Owens, Jenny Tan, Peter Michael Wovkulich
-
Patent number: 8889682Abstract: This application discloses compounds according to generic Formula I: wherein the variables are defined as described herein, and which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: GrantFiled: August 16, 2012Date of Patent: November 18, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Saul Jaime-Figueroa, Francisco Javier Lopez-Tapia, Yan Lou, Timothy D. Owens
-
Patent number: 8871760Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, and R3 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.Type: GrantFiled: September 15, 2010Date of Patent: October 28, 2014Assignee: Roche Palo Alto LLCInventors: Christine E. Brotherton-Pleiss, Ralph New Harris, III, Bradley E. Loe, Francisco Javier Lopez-Tapia, Pankaj D. Rege, David Bruce Repke, Russell Stephen Stabler, Keith Adrian Murray Walker
-
Patent number: 8742098Abstract: This application discloses compounds according to generic Formula I: wherein the variables are defined as described herein, and which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: GrantFiled: December 6, 2012Date of Patent: June 3, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Francisco Javier Lopez-Tapia, Yan Lou
-
Patent number: 8481540Abstract: This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: GrantFiled: August 11, 2011Date of Patent: July 9, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Steven Joseph Berthel, Roland Joseph Billedeau, Christine E. Brotherton-Pleiss, Fariborz Firooznia, Stephen Deems Gabriel, Xiaochun Han, Ramona Hilgenkamp, Saul Jaime-Figueroa, Buelent Kocer, Francisco Javier Lopez-Tapia, Yan Lou, Lucja Orzechowski, Timothy D. Owens, Jenny Tan, Peter Michael Wovkulich
-
Patent number: 8435990Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5, Ra and Rb are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.Type: GrantFiled: July 30, 2010Date of Patent: May 7, 2013Assignee: Roche Palo Alto LLCInventors: Christine E. Brotherton-Pleiss, Joan Marie Caroon, Francisco Javier Lopez-Tapia, Keith Adrian Murray Walker
-
Publication number: 20130045965Abstract: This application discloses compounds according to generic Formula I: wherein the variables are defined as described herein, and which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: ApplicationFiled: August 16, 2012Publication date: February 21, 2013Inventors: Christine E. Brotherton-Pleiss, Saul Jaime-Figueroa, Francisco Javier Lopez-Tapia, Yan Lou, Timothy D. Owens